Skip to main content
. 2004 Dec;78(23):13207–13215. doi: 10.1128/JVI.78.23.13207-13215.2004

FIG. 2.

FIG. 2.

(A) Human sera were derived from patients in Belgium, the United Kingdom, and The Netherlands (EUR); Stanford, Calif., and New York, N.Y. (USA); many different countries in sub-Saharan Africa (AFRICA); and Japan as the sole representative of Asia. Sera were scored positive when sufficient neutralizing activity (NAbs) was present in serum diluted 1/32 to neutralize Ad5 (black bars) or Ad11 (grey bars) by ≥90% as measured by inhibition of luciferase activity in A549 cells (31). (B) Box-and-whisker plots of Ad-NAb titers against Ad5 (white bars) and Ad11 (grey bars) in positive serum samples. Horizontal bars within the boxed area indicate the median Ad-NAb titer. Serum titers were defined by the dilution at which ≥90% infection inhibition was observed. (C) Percentages of serum samples positive for Ad5 (black bars) or Ad11 (grey bars) at 24 or 72 months after entry into the Amsterdam cohort studies on AIDS initiative when patients were immune competent and asymptomatic (24m) or severely immune compromised and symptomatic (72m). Sera were scored positive when sufficient neutralizing activity was present in serum (NAbs) diluted 1/32 to neutralize Ad5 (black bar) or Ad11 (grey bar) by ≥90% as measured by inhibition of luciferase activity in A549 cells. (D) Box-and-whisker plots of Ad-NAb titers against Ad5 (white bars) and Ad11 (grey bars) in positive serum samples; horizontal bars within the boxed area indicate the median Ad-NAb titer. Serum titers were defined by the dilution at which ≥90% infection inhibition was observed.